Thursday, December 20, 2012

Quote of the Day

“Patients who choose a market basket of brand-name drugs instead of clinically equivalent generic alternatives are being charged a higher premium for this decision than ever before. That larger-than-necessary cost is being shared across the member and the plan sponsor. Both can realize savings when members choose lower-cost therapeutically equivalent generic drugs.”

— Sharon Frazee, Ph.D., VP for research and new solutions at Express Scripts, told AIS’s Drug Benefit News.

No comments:

Post a Comment